Literature DB >> 34173972

Risk factor for vital signs elevation during percutaneous microwave ablation of liver tumor under deep sedation.

Wen-Tao Wu1, Wei-Zhong Zhou2, Qing-Quan Zu2, Zhen-Yu Jia2, Bin Leng2, Sheng Liu2, Hai-Bin Shi2, Yu Chen3.   

Abstract

PURPOSE: To evaluate the frequency and the degree of vital signs elevation, as well as to elucidate the risk factors for elevation of cardiopulmonary parameters.
MATERIALS AND METHODS: We retrospectively evaluated the medical records of 101 patients who received microwave ablation (MWA) under deep sedation with propofol. Univariate analysis followed by multivariate linear regression analysis was performed to determine the risk factors associated with the elevation of cardiopulmonary parameters.
RESULTS: The heart rate (HR), mean blood pressure (BP) and respiratory rate (RR) were elevated in 53.5%, 45.5% and 30.7%. Hyperhemodynamic state (mean BP or HR increased > 30% of the baseline) and high RR (RR > 20 times/min) were detected in 23.8% and 13.9%. Age ≤ 50 years was signifiant for mean BP and HR elevation (p = 0.032; p = 0.027), ablation zone abutting the parietal peritoneum (p = 0.001; p = 0.001; p < 0.001) and the diaphragm (p = 0.001) were risk factors for BP and RR elevation.
CONCLUSIONS: Elevations in HR and BP are common. Risk factors for vital signs elevation include ablation zone abutting the parietal peritoneum and the diaphragm, as well as young age. These findings help devise strategies for anesthetic management.
© 2021. Japan Radiological Society.

Entities:  

Keywords:  Anesthesia; Liver; Microwave ablation; Risk factor; Vital signs

Mesh:

Year:  2021        PMID: 34173972     DOI: 10.1007/s11604-021-01158-w

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  25 in total

1.  Life-threatening hypertensive crises in two patients undergoing hepatic radiofrequency ablation.

Authors:  Gary Onik; Casey Onik; Irene Medary; Debra M Berridge; Debra S Chicks; Lester T Proctor; Thomas C Winter; Fred T Lee
Journal:  AJR Am J Roentgenol       Date:  2003-08       Impact factor: 3.959

2.  Prospective analysis of the pattern and risk for severe vital sign changes during percutaneous radiofrequency ablation of the liver under opioid analgesia.

Authors:  Min Jung Park; Young-sun Kim; Hyunchul Rhim; Hyo Keun Lim; Byung Seop Shin; Dongil Choi; Min Woo Lee; Dong Hwan Kim
Journal:  AJR Am J Roentgenol       Date:  2010-03       Impact factor: 3.959

3.  The effects of anesthetic technique on cancer recurrence in percutaneous radiofrequency ablation of small hepatocellular carcinoma.

Authors:  Renchun Lai; Zhenwei Peng; Dongtai Chen; Xudong Wang; Wei Xing; Weian Zeng; Minshan Chen
Journal:  Anesth Analg       Date:  2011-11-21       Impact factor: 5.108

4.  A Case of Hypertensive Crisis without a Surge in Adrenal Hormones after Radiofrequency Ablation as a Treatment for Primary Hepatocellular Carcinoma.

Authors:  Kyung Jin Lee; Soo Hyung Ryu
Journal:  Korean J Gastroenterol       Date:  2017-10-25

Review 5.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

6.  Controlled sedation with alphaxalone-alphadolone.

Authors:  M A Ramsay; T M Savege; B R Simpson; R Goodwin
Journal:  Br Med J       Date:  1974-06-22

7.  Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience.

Authors:  Robert C G Martin; Charles R Scoggins; Kelly M McMasters
Journal:  Ann Surg Oncol       Date:  2009-08-26       Impact factor: 5.344

8.  Prevention of vagotonia and pain during radiofrequency ablation of liver tumors.

Authors:  Shinichiro Nakamura; Kazuhiro Nouso; Hideki Onishi; Kenji Kuwaki; Hiroaki Hagihara; Yasuto Takeuchi; Nozomu Wada; Yuki Morimoto; Koji Miyahara; Tetsuya Yasunaka; Fusao Ikeda; Yasuhiro Miyake; Yoshiyuki Kobayashi; Hidenori Shiraha; Shinichi Ishikawa; Akinobu Takaki; Kazuhide Yamamoto
Journal:  Hepatol Res       Date:  2014-04-02       Impact factor: 4.288

9.  Malignant liver tumors: treatment with percutaneous microwave ablation--complications among cohort of 1136 patients.

Authors:  Ping Liang; Yang Wang; XiaoLing Yu; Baowei Dong
Journal:  Radiology       Date:  2009-03-20       Impact factor: 11.105

10.  Propofol Compared to Midazolam Sedation and to General Anesthesia for Percutaneous Microwave Ablation in Patients with Hepatic Malignancies: A Single-Center Comparative Analysis of Three Historical Cohorts.

Authors:  Robbert S Puijk; Valentijn Ziedses des Plantes; Sanne Nieuwenhuizen; Alette H Ruarus; Laurien G P H Vroomen; Marcus C de Jong; Bart Geboers; Caroline J Hoedemaker-Boon; Deirdre H Thöne-Passchier; Ceylan C Gerçek; Jan J J de Vries; Petrousjka M P van den Tol; Hester J Scheffer; Martijn R Meijerink
Journal:  Cardiovasc Intervent Radiol       Date:  2019-06-26       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.